Drug
Panitumumab
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | EGFR-Targeting |
| Group | Anti-EGFR mAb |
| Mechanism of Action | Anti-EGFR antibody |
| Half-life | 7,5 d |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing by blocking nuclear EGFR–DNA-PK–mediated NHEJ, G1 arrest, and ADCC. Because EGFR-dependent repair and proliferation also operate in skin and mucosa, this mechanism is not tumor-selective and can sensitize normal epithelium in the field, providing a rationale for aggravated in-field mucositis and radiation dermatitis (Costa et al., Supportive Care in Cancer, 2025; Machtay et al., Journal of Clinical Oncology, 2025).
Data on this page refer exclusively to patients treated with
Panitumumab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
Anti-EGFR mAb group page.